Rota E, Bazzan M, Fantino G. Fondaparinux-related throm- bocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008;99(4):779-781. 2012 American College of Chest Physicians by Kimberly Henricks on February 10, 2012 chestjournal.chestpubs.org Downloaded from www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e43S ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy. 2005;25(2):157-164. 229. Bartholomew J. Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia. Chest. 2005;127(suppl 2):27S-34S. 230. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with hepa- rin-induced thrombocytopenia. Clin Appl Thromb Hemost. 2005;11(3):279-287. 231. S rensen B, Ingerslev J. A direct thrombin inhibitor stud- ied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost. 2006;96(4):446-453. 225. Hursting MJ, Alford KL, Becker JC, et al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost. 1997;23(6):503-516. 226. Swan SK, Hursting MJ. The pharmacokinetics and phar- macodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy. 2000;20(3): 318-329. 227. Warkentin TE, Greinacher A, Craven S, Dewar L, Sheppard JA, Ofosu FA. Differences in the clinically effec- tive molar concentrations of four direct thrombin inhibi- tors explain their variable prothrombin time prolongation. Thromb Haemost. 2005;94(5):958-964. 228. Arpino PA, Demirjian Z, Van Cott EM. Use of the chromo- genic factor X assay to predict the international normalized 2012 American College of Chest Physicians by Kimberly Henricks on February 10, 2012 chestjournal.chestpubs.org Downloaded from